Windlas Biotech and Mateon Therapeutics Launch India's First Combined Lung Therapy and Ai Telemedicine 360 Solution to Transform Respiratory Wellness - The Pharma Times | Pharma & Health Care News Portal
EDGAR Filing Documents for 0001493152-21-001207
COVID Pandemic Hastens Search For New Technology And CRO Partner
MATEON THERAPEUTICS AKTIE | Aktienkurs | US6283411097 | News | A14Y0U | finanzen.net
Mateon Therapeutics Company Profile: Valuation, Investors, Acquisition | PitchBook
A Covid-19 treatment plan slowly emerges | Evaluate
NantCell Binding Termsheet | MATEON THERAPEUTICS INC | Business Contracts | Justia
EX-4.1
Articles about Mateon Therapeutics, Inc.
Dr. Anthony E. Maida will be presenting at the Marcus Evans Evolution Summit
Mateon and PointR to merge into AI-driven oncology firm
Joint Venture Agreement relating to GMP Biotechnology Limited | MATEON THERAPEUTICS INC | Business Contracts | Justia
Consulting Agreement by and between the Company and Artius, | MATEON THERAPEUTICS INC | Business Contracts | Justia
Blockchain-Fueled Company Mateon Develops Phase 3 Clinical Drug Candidate, Against COVID-19 - OT-101 – Blockchain News, Opinion, TV and Jobs
Mateon Therapeutics - BIO Investor Forum | BIO
MATN: Positive Early Results for ARTIVeda™ in Treating COVID-19…
FinData: Share Price for NASDAQ, MATN - Mateon Therapeutics Inc.
Windlas Biotech, Mateon Therapeutics launch drug-device plus lung therapy platform - Express Pharma
Mateon Therapeutics Archives - IndiaMedToday
Mateon Completes Its Acquisition of PointR Data Inc. - DATAVERSITY
Keeping an eye on Mateon Therapeutics (OTCQB: MATN) says GEN - Genetic Engineering & Biotechnology News - EmergingGrowth.com
Corporate Videos – Oncotelic
Mateon Therapeutics (MATN) expands its management team to accelerate the commercialization and development of OT-101 for COVID-19 - EmergingGrowth.com
Mateon launches antiviral programme focussed on Covid-19
Mateon Halts Lead Candidate Development, Axes 60% of Workforce
Zacks Small-Cap Research
